Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
J Neurooncol
; 132(2): 231-238, 2017 04.
Article
en En
| MEDLINE
| ID: mdl-28283800
ABSTRACT
Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Encéfalo
/
Neoplasias Encefálicas
/
Transducción de Señal
/
Apoptosis
/
Proliferación Celular
/
Ciclooxigenasa 2
/
Glioma
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Neurooncol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Japón